G1 Therapeutics (GTHX) PT Raised to $41 at Raymond James, Following Discussion With Management Following Clinical Update
Tweet
Share
E-mailGet Alerts GTHX Hot Sheet
Price: $7.15 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Raymond James analyst Dane Leone raised the price target on G1 Therapeutics (NASDAQ: GTHX) to $41.00 (from $21.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Downgrades Brother Industries Ltd (6448:JP) to Neutral
- Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
- GMO Payment Gateway Inc (3769:JP) PT Lowered to JPY13,200 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
